Previous 10 | Next 10 |
Ironwood Pharmaceuticals (NASDAQ:IRWD): Q3 Non-GAAP EPS of $0.33 beats by $0.01; GAAP EPS of $0.34 beats by $0.03. Revenue of $103.74M (+0.3% Y/Y) misses by $1.53M. Press Release For further details see: Ironwood Pharmaceuticals EPS beats by $0.01, misses on revenue
– LINZESS ® (Iinaclotide) prescription demand growth increased 12% year-over-year; LINZESS U.S. net sales of $253 million, an increase of 5% year-over-year – – Total revenue of $104 million; U.S. LINZESS collaboration revenue of $100 million...
IND for CNP-104 Accepted by FDA; Clinical Trials Planned for the End of 2021 Ironwood to Make a Payment of approximately $20 Million in Upfront and Near-Term Milestones and up to $475 Million in Long-Term Commercial and Regulatory Milestones and Royalties to COUR I...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is $0.32 (+39.1% Y/Y) and the consensus Revenue Estimate is $105.27M (+1.7% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates ...
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration. Cyclerion has upcoming phase 2 data coming out in H12022 that will be a major inflection point to potentially open up new opportunities for the distr...
- Ironwood to Also Present Data Highlighting Impact of Linaclotide on Abdominal and Bowel-Related Symptoms in Adult Patients with IBS-C - - Separate Surveys Will Highlight Disease Prevalence and Burden Among Patients with GI Conditions - Ironwood Pharmaceuticals, I...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 4, 2021. Individuals interested in participating in the call should dial (888) 330-3181 (U.S....
P/E (5.61), EV/EBITDA (9.28), and Price/Sales (5.37) are 30-80% lower than the sector medians. Balance sheet of IRWD has been steadily improving over the past several years. Revenue has grown since 2016 (CAGR of 21.10%). I don’t believe this low valuation is justified, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Covid-19 pandemic brought a renewed interest into the healthcare sector, and with the surging Delta variant raging across the country, that interest isn’t expected to dissipate anytime soon. Due to that attentio...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS ® (linaclotide) based on clinical safety data that has been generated thus far in pediatric ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...